SHANGHAI – Pick an issue or an industry, China’s complex problems can seem intractable with much-touted reforms dismally ineffectual. But with the power of China’s top-down decision-making, there are times when the government sets a new course and far-reaching change follows swiftly if not necessarily smoothly. Read More
Biogen Inc.’s third quarter earnings brought a much-needed – if somewhat superficial – rebound, as revenues for the three months ending Sept. 30 beat consensus estimates and executives outlined a strategy for getting the company back on track after a dismal first half of the year. Read More
SAN FRANCISCO – This year has been paved with more legislative and regulatory twists and turns for biopharma than the yellow brick road, and the end is not yet in sight, according to a panel of legal, business and regulatory experts at the 2015 BIO Investor Forum in San Francisco. Read More
SAN FRANCISCO – With seven consecutive quarters seeing more than $10 billion deployed to the start-up ecosystem, “it’s a great time to be an entrepreneur in America,” National Venture Capital Association president and CEO Bobby Franklin said recently. But try telling that to biotech companies seeking a series A today. Read More
Judging by the questions the FDA is posing, much of Friday’s Arthritis Advisory Committee (AAC) meeting on Ardea Biosciences Inc.’s gout drug Zurampic will focus on the dosing and safety of the oral drug, in light of what the agency considers its “modest” treatment effect. Read More
RIO DE JANEIRO – Difficulties carrying out clinical trials in Brazil may be hurting the development of the biotech sector in Latin American countries, particularly Brazil. Read More
DUBLIN – Novartis AG made three additions to its immuno-oncology portfolio Wednesday, further evidence of the non-stop deal-making ferment in what remains the pharmaceutical industry’s most lively area of drug development. Read More
Oncodesign SA, of Dijon, France, and Ipsen SA, of Paris, presented discovery and characterization data at the Society for Neurosciences meeting in Chicago for ODS2005294, a LRRK2 inhibitor jointly discovered in a January 2012 research collaboration. Read More
Kura Oncology Inc., of La Jolla, Calif., has filed its S-1 with the SEC to raise up to $86 million in an IPO. In March the company completed a reverse merger and closed a $60 million private placement with a syndicate of venture funds. Read More
Delmar Pharmaceuticals Inc., of Vancouver, British Columbia, said the 14-patient expansion cohort of its phase II study of VAL-083 (dianhydrogalactitol) in patients with refractory glioblastoma multiforme is now fully enrolled. Read More
